DADC
VNDA icon

D.A. Davidson & Co’s Vanda Pharmaceuticals VNDA Stock Holding History

D.A. Davidson & Co’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,400
Closed -$11K – 2404
2016
Q1 		$11K Buy
+1,400
New +$11.5K ﹤0.01% 1893

Other funds holding VNDA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.A. Davidson & Co's VNDA Position: Q2 2016 in Review

D.A. Davidson & Co sold out of Vanda Pharmaceuticals (VNDA) in Q2 2016, closing a stake of 1,400 shares — an estimated $11K sold.

D.A. Davidson & Co first reported a position in VNDA in Q1 2016 and held it in 1 quarter. The position peaked at $11K in Q1 2016. 115 funds tracked by Wall St. Rank hold VNDA as of Q2 2016.

  • D.A. Davidson & Co reported no remaining Vanda Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • D.A. Davidson & Co sold 1,400 Vanda Pharmaceuticals shares in Q2 2016, an estimated $11K.
  • D.A. Davidson & Co first reported a position in Vanda Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • D.A. Davidson & Co's Vanda Pharmaceuticals position peaked at $11K in Q1 2016.
  • 115 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2016.

Based on D.A. Davidson & Co's 13F filing for Q2 2016, filed 15 Aug 2016.